FDA to Allow Bracco to Import Iomeron Iodinated Contrast Media as Shortage Drags On
The imaging agent is approved for use in 50 countries in Europe and Asia, but is not currently approved in the US.
In the latest move to further relieve the burden of the ongoing shortage of iodinated contrast media, the US FDA has granted import discretion to Bracco Diagnostics for its nonionic iodinated contrast media agent Iomeron (iomeprol injection) for use in imaging procedures in adults.
As a result of the discretion, the product will be temporarily available in the US starting at the end of August.
"We are proud that the company has worked proactively with the FDA to address the shortage of iodinated contrast agents in the U.S. market," said Bracco Diagnostics chief executive officer Jeff Fleming, in a statement.
Iomeron is indicated for use in numerous types of angiography, CT, and urography, including cerebral angiography, thoracic angiography, abdominal angiography, peripheral angiography, intravenous digital subtraction angiography, intraarterial digital subtraction, visualization in computed tomography and intravenous urography.
The agent, which is manufactured in Germany and Italy alongside Bracco's FDA-approved iodinated contrast media agent iopamidol (Isovue), will be availabe in the US in concentrations ranging from 250 mg iodine/mL to 400 mg iodine/mL. Notably, in a letter to health care providers, Bracco points out differences in indications and physico-chemical properties between Iomeron and FDA-approved agents iohexol (Omnipaque), iodixanol (Visipaque), iopromide (Ultravist), ioversol (Optiray), and iopamidol (Isovue).
Earlier this month, the FDA also granted Bayer the ability to import and distribute foreign-labeled iopromide (Ultravist) in the US.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging
August 2nd 2025An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 2nd 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
August 2nd 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 2nd 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
